Reactivating SLFN11 via HDAC inhibitors restores cancer cell sensitivity to DNA-damaging agents [21,22], while SLFN12 influences immune regulation and chemotherapy response in triple-negative breast cancer [23]. Here, SLFN12 is linked to cancer.